Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

The Pharma Letter

September 3, 2022

Abivax completes oversubscribed 49.2 million-euro cross-over financing

L'Usine Nouvelle

September 2, 2022

Abivax récolte plus de 49 millions d’euros pour avancer sur un traitement de la rectocolite hémorragique

Capital

September 2, 2022

Abivax : financement de 49,2 millions d’euros

CFNEWS

September 2, 2022

Abivax se tourne vers les Etats-Unis

Les Echos investir

September 2, 2022

Abivax lève près de 50 millions d’euros de nouveaux financements

  • 1
  • 2
  • 3

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn